Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center

  • Kim, Min-Sun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Song, Ari (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Im, Minji (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, June (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, I-Seok (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Song, Jinyoung (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yang, Aram (Department of Pediatrics, Inha University College of Medicine) ;
  • Kim, Jinsup (Department of Pediatrics, Hanyang University College of Medicine) ;
  • Kwon, Eun-Kyung (Department of Pediatrics, Samsung Medical Center) ;
  • Choi, Eu-Jin (Department of Pediatrics, Samsung Medical Center) ;
  • Han, Sun-Ju (Samsung Biomedical Research Institute) ;
  • Park, Hyung-Doo (Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cho, Sung Yoon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jin, Dong-Kyu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2018.08.30
  • Accepted : 2018.10.22
  • Published : 2019.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Pompe disease (PD) is an autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase resulting from pathogenic GAA variants. This study describes the clinical features, genotypes, changes before and after enzyme replacement therapy (ERT), and long-term outcomes in patients with infantile-onset PD (IOPD) and late-onset PD (LOPD) at a tertiary medical center. Methods: The medical records of 5 Korean patients (2 male, 3 female patients) diagnosed with PD between 2002 and 2013 at Samsung Medical Center in Seoul, Republic of Korea were retrospectively reviewed for data, including clinical and genetic characteristics at diagnosis and clinical course after ERT. Results: Common initial symptoms included hypotonia, cyanosis, and tachycardia in patients with IOPD and limb girdle weakness in patients with LOPD. Electrocardiography at diagnosis revealed hypertrophic cardiomyopathy in all patients with IOPD who showed a stable disease course during a median follow-up period of 10 years. Patients with LOPD showed improved hepatomegaly and liver transaminase level after ERT. Conclusion: As ERT is effective for treatment of PD, early identification of this disease is very important. Thus, patients with IOPD should be considered candidates for clinical trials of new drugs in the future.

Keywords

References

  1. Di Mauro S. Muscle glycogenoses: an overview. Acta Myol 2007;26:35-41.
  2. Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord 2015;25:321-32. https://doi.org/10.1016/j.nmd.2014.12.004
  3. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342-53. https://doi.org/10.1016/S0140-6736(08)61555-X
  4. Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol 2013;70:923-7. https://doi.org/10.1001/2013.jamaneurol.486
  5. Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 2013;54:219-27. https://doi.org/10.1016/j.pedneo.2013.03.009
  6. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40. https://doi.org/10.1542/peds.112.2.332
  7. Dragulescu A, Mertens L, Friedberg MK. Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: problems and limitations. Circ Cardiovasc Imaging 2013;6:254-61. https://doi.org/10.1161/CIRCIMAGING.112.000175
  8. van Gelder CM, van Capelle CI, Ebbink BJ, Moor-van Nugteren I, van den Hout JM, Hakkesteegt MM, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012;35:505-11. https://doi.org/10.1007/s10545-011-9404-7
  9. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid $\alpha$-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3389-420.
  10. Raben N, Plotz P, Byrne BJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002;2:145-66. https://doi.org/10.2174/1566524024605789
  11. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999;7:713-6. https://doi.org/10.1038/sj.ejhg.5200367
  12. Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during longterm follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009;19:113-7. https://doi.org/10.1016/j.nmd.2008.11.007
  13. Gungor D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011;6:34. https://doi.org/10.1186/1750-1172-6-34
  14. Cho A, Kim SJ, Lim BC, Hwang H, Park JD, Kim GB, et al. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy. J Child Neurol 2012;27:319-24. https://doi.org/10.1177/0883073811420295
  15. de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 2012;7:73. https://doi.org/10.1186/1750-1172-7-73
  16. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010;257:91-7. https://doi.org/10.1007/s00415-009-5275-3
  17. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6. https://doi.org/10.1016/j.jpeds.2005.11.033
  18. Werneck LC, Lorenzoni PJ, Kay CS, Scola RH. Muscle biopsy in Pompe disease. Arq Neuropsiquiatr 2013;71:284-9. https://doi.org/10.1590/0004-282X20130022
  19. Hermans MM, van Leenen D, Kroos MA, Reuser AJ. Mutation detection in glycogen storage-disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun 1997;241:414-8. https://doi.org/10.1006/bbrc.1997.7811
  20. Ko TM, Hwu WL, Lin YW, Tseng LH, Hwa HL, Wang TR, et al. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 1999;13:380-4. https://doi.org/10.1002/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A
  21. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7. https://doi.org/10.1164/ajrccm.166.1.at1102
  22. Liu X, Wang Z, Jin W, Lv H, Zhang W, Que C, et al. Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation. BMC Med Genet 2014;15:141. https://doi.org/10.1186/s12881-014-0141-2
  23. Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantileonset Pompe disease. Cochrane Database Syst Rev 2017;11:CD011539.
  24. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 2012;160C:59-68. https://doi.org/10.1002/ajmg.c.31318
  25. Lin CY, Shieh JJ. Molecular study on the infantile form of Pompe disease in Chinese in Taiwan. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1996;37:115-21.
  26. Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, et al. Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase". J Hum Genet 2007;52:898-906. https://doi.org/10.1007/s10038-007-0191-9
  27. Huie ML, Menaker M, McAlpine PJ, Hirschhorn R. Identification of an E689K substitution as the molecular basis of the human acid alphaglucosidase type 4allozyme (GAA*4). Ann Hum Genet 1996;60:365-8. https://doi.org/10.1111/j.1469-1809.1996.tb00433.x
  28. Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet 2008;16:875-9. https://doi.org/10.1038/ejhg.2008.34
  29. Dagnino F, Stroppiano M, Regis S, Bonuccelli G, Filocamo M. Evidence for a founder effect in Sicilian patients with glycogen storage disease type II. Hum Hered 2000;50:331-3. https://doi.org/10.1159/000022938
  30. Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep 2017;14:3-9. https://doi.org/10.1016/j.ymgmr.2017.10.009
  31. Amarinthnukrowh P, Tongkobpetch S, Kongpatanayothin A, Suphapeetiporn K, Shotelersuk V. p.D645E of acid $\alpha$-glucosidase is the most common mutation in thai patients with infantile-onset pompe disease. Genet Test Mol Biomarkers 2010;14:835-7. https://doi.org/10.1089/gtmb.2010.0038
  32. Gort L, Coll MJ, Chabas A. Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation. Mol Genet Metab 2007;92:183-7. https://doi.org/10.1016/j.ymgme.2007.05.011
  33. Park HD, Lee DH, Choi TY, Lee YK, Lee SY, Kim JW, et al. Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients. Ann Clin Lab Sci 2013;43:311-6.
  34. Hagemans ML, Laforet P, Hop WJ, Merkies IS, Van Doorn PA, Reuser AJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord 2007;17:537-43. https://doi.org/10.1016/j.nmd.2007.03.006
  35. Ko JM, Park KS, Kang Y, Nam SH, Kim Y, Park I, et al. A new integrated newborn screening workflow can provide a shortcut to differential diagnosis and confirmation of inherited metabolic diseases. Yonsei Med J 2018;59:652-61. https://doi.org/10.3349/ymj.2018.59.5.652

Cited by

  1. The Novel Compound Heterozygous Mutations of GAA Gene in Mainland Chinese Patient with Classic Infantile-Onset Pompe Disease : A Case Report and Literature Review vol.61, pp.1, 2020, https://doi.org/10.1536/ihj.19-241
  2. Considerations for evaluating the effectiveness and longterm outcome of enzyme replacement therapy in Pompe disease vol.63, pp.1, 2019, https://doi.org/10.3345/kjp.2018.07402
  3. Two Approaches for a Genetic Analysis of Pompe Disease: A Literature Review of Patients with Pompe Disease and Analysis Based on Genomic Data from the General Population vol.8, pp.7, 2019, https://doi.org/10.3390/children8070601